Pharmacokinetic profile of Optivate ® (high‐purity factor VIII/von Willebrand factor concentrate) in treating von Willebrand disease

Haemophilia ◽  
2015 ◽  
Vol 22 (1) ◽  
Author(s):  
R. Shaikh‐Zaidi ◽  
A. Lubetsky ◽  
A. Inbal ◽  
C. Dash
Keyword(s):  
Factor Viii ◽  
Von Willebrand Factor ◽  
High Purity ◽  
Pharmacokinetic Profile ◽  
Von Willebrand Disease ◽  
Factor Concentrate ◽  
Von Willebrand ◽  
Willebrand Factor

Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study

Blood ◽  
2002 ◽  
Vol 99 (2) ◽  
pp. 450-456 ◽  
Author(s):  
Pier M. Mannucci ◽  
Juan Chediak ◽  
Wahid Hanna ◽  
John Byrnes ◽  
Marlies Ledford ◽  
...  
Keyword(s):  
Factor Viii ◽  
Von Willebrand Factor ◽  
High Purity ◽  
Bleeding Time ◽  
Von Willebrand Disease ◽  
Invasive Procedures ◽  
Bleeding Episodes ◽  
Type 3 ◽  
Von Willebrand ◽  
Willebrand Factor

Abstract Among patients with von Willebrand disease (VWD) who are unresponsive to desmopressin therapy, replacement with plasma-derived concentrates is the treatment of choice. Because prospective studies are lacking, such treatment has been largely empirical. A multicenter, prospective study has been conducted in 81 patients with VWD (15 patients with type 1, 34 with type 2, and 32 with type 3 disease) to investigate the efficacy of a high-purity factor VIII/von Willebrand factor (FVIII/VWF) concentrate for treatment of bleeding and surgical prophylaxis. Two preparations of the concentrate—one virally inactivated with solvent detergent, the other with an additional heat-treatment step—were evaluated. Pharmacokinetic parameters were similar for both preparations. Using pre-established dosages based on the results of pharmacokinetic studies, 53 patients were administered either preparation for the treatment of 87 bleeding episodes, and 39 patients were treated prophylactically for 71 surgical or invasive procedures. Sixty-five (74.7%) and 10 (11.5%) of the bleeding episodes were controlled with 1 or 2 infusions, respectively. Patients with severe type 3 VWD typically required more infusions and higher doses, at shorter time intervals, than did patients with generally milder types 1 and 2. Among patients undergoing surgical procedures, blood loss was lower than that predicted prospectively, and losses exceeding the predicted value did not correlate with the postinfusion skin bleeding time. In conclusion, the concentrate effectively stopped active bleeding and provided adequate hemostasis for surgical or invasive procedures, even in the absence of bleeding time correction.

scholarly journals Management of von Willebrand disease with a factor VIII‐poor von Willebrand factor concentrate: Results from a prospective observational post‐marketing study

2020 ◽  
Vol 18 (8) ◽  
pp. 1922-1933 ◽  
Author(s):  
Jenny Goudemand ◽  
Françoise Bridey ◽  
Ségolène Claeyssens ◽  
Nathalie Itzhar‐Baïkian ◽  
Annie Harroche ◽  
...  
Keyword(s):  
Factor Viii ◽  
Von Willebrand Factor ◽  
Von Willebrand Disease ◽  
Post Marketing ◽  
Factor Concentrate ◽  
Von Willebrand ◽  
Willebrand Factor

Use of von Willebrand Factor Concentrate in Inherited von Willebrand Disease: How Often Is It Useful to Add Factor VIII?

2020 ◽  
Vol 34 (2) ◽  
pp. 128-129
Author(s):  
Nicolas Drillaud ◽  
Laurent Ardillon ◽  
Catherine Ternisien ◽  
Jean Baptiste Valentin ◽  
Marc Fouassier ◽  
...  
Keyword(s):  
Factor Viii ◽  
Von Willebrand Factor ◽  
Von Willebrand Disease ◽  
Factor Concentrate ◽  
Von Willebrand ◽  
Willebrand Factor
Sign in / Sign up

Export Citation Format

Share Document